xtremely-low-birth-weight (ELBW; birth weight ≤1000 g) infants often have low plasma and tissue concentrations of vitamin A (retinol), 1 which may increase the risk for bronchopulmonary dysplasia (BPD; neonatal chronic lung disease). 2 Clinical trials have demonstrated that vitamin A supplementation decreases BPD and/or death. [3] [4] [5] A recent large multicenter trial conducted by the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network showed that vitamin A given as an intramuscular injection at a dose of 5000 IU 3 times per week for 4 weeks decreased the risk of the combined outcome of BPD and/or death in ELBW infants. 4 The dosing regimen followed in this trial was based on a pilot study in which an intramuscular dose of 5000 IU/dose 3 times per week led to mean serum retinol concentrations >25 µg/dL. 6 However, 22% of infants in the treatment group of the NICHD trial had a high retinol dose response (RDR) suggestive of low or absent vitamin A stores, and 25% had low serum retinol concentrations (<20 µg/dL) 4 even after receiving vitamin A in doses considerably larger than those used in previous trials. One conclusion of the NICHD trial was that study of higher doses was warranted.
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The regimen used in the NICHD trial necessitates 12 intramuscular injections. If similar retinol levels could be achieved with less frequent injections, pain and discomfort in ELBW neonates, personnel time, and the risk for infection and pharmacy error might be reduced. Although vitamin A supplementation has been shown to be beneficial in very low birth weight neonates, 7 the optimal dosing regimen has yet to be determined. 5 This study was therefore designed to compare three vitamin A dosing regimens: the standard regimen, 4 a higher dose regimen, and a once-per-week regimen. It was hypothesized that as compared with the standard dosing regimen, the higher dose regimen would lead to higher retinol concentrations and decreased evidence of biochemical vitamin A deficiency and that the once-per-week regimen would lead to equivalent concentrations of serum retinol and prevalence of biochemical deficiency.
METHODS
This study was a randomized, partially masked trial comparing the standard, the higher dose, and the once-per-week regimens. The protocol was approved by the institutional review board, and informed parental consent was obtained before random assignment. The study design was similar to the NICHD Neonatal Network trial with respect to entry criteria, ages at retinol administration, and biochemical and clinical assessment methods (Tyson et al, 1999) . Entry criteria were birth weight 401 to 1000 g and admitted to the NICU at the University of Alabama at Birmingham (UAB); mechanical ventilation or continuous positive airway pressure (CPAP) or supplemental oxygen at 24 hours' postnatal age; and age ≥24 hours and ≤96 hours (with random assignment and administration of first dose of drug by 96 hours). Exclusion criteria were any of the following: one or more major congenital anomalies, congenital nonbacterial infection with overt signs at birth, and terminal illness as evidenced by pH <6.8 for >2 hours or persistent bradycardia (heart rate <100 bpm) associated with hypoxia for >2 hours.
Infants were allocated to standard, higher dose, or onceper-week groups by random assignment stratified by birth weight (401-750 g, 751-1000 g), using shuffled blocks (of sizes 3, 6, or 9) of sealed opaque envelopes. Vitamin A (Aquasol A; water-miscible retinyl palmitate; Astra USA, Inc, Westborough, Mass), 5000 IU (0.1 mL) or 10,000 IU (0.2 mL), was given by intramuscular injection with a 0.3-mL insulin syringe with a 29-gauge needle on Mondays, Wednesdays, and Fridays to the standard group and higher dose groups, respectively. For infants in the once-per-week group, 15,000 IU (0.3 mL) was given by intramuscular injection on either Monday, Wednesday, or Friday (whichever was the next closest day after random assignment). As in the NICHD trial, 4 the doses were not adjusted for body weight. The average intake excluding supplementation was 500 to 1000 IU/kg per day in the first 10 days and subsequently 1000 to 1500 IU/kg per day from the 10th day to the end of the first month.
Data collection was performed prospectively by an experienced research nurse, using written definitions. Serum retinol was measured by HPLC at baseline (before the first dose) and at study day 28. The HPLC method was specific for retinol, unlike fluorometric methods that measure retinol, retinyl esters, and related compounds. The sample obtained on study day 28 was also used for determination of retinol binding protein (RBP) by radial immunodiffusion (The Binding Site, Inc, San Diego, Calif ). In addition, the RDR was measured on study day 28 by intramuscular injection of 2000 IU/kg of retinyl palmitate followed 2 hours later by collection of blood for serum retinol levels. 4 As described in the NICHD trial, 4 the RDR was calculated as the change in serum retinol concentration divided by the preinjection concentration.
The predefined primary outcome of the study was the serum retinol level on study day 28. Secondary outcomes included RDR, RBP, proportion of infants with biochemical evidence of vitamin A deficiency (serum retinol <20 µg/dL, RDR >10%, 4 and/or RBP <2.5 mg/dL), 7 evidence of toxicity (as described below), bronchopulmonary dysplasia or death at 36 weeks' postmenstrual age, and death by 36 weeks' postmenstrual age. Other secondary outcomes included neonatal sepsis (one or more positive blood cultures), retinopathy of prematurity (threshold ROP diagnosed by a pediatric ophthalmologist), 8 and necrotizing enterocolitis (Bell stage II or higher) 9 by hospital discharge or by 120 days of hospital stay.
To verify the safety of the regimens, evaluations for signs of subtle toxicity were initially performed at frequent intervals. These evaluations were performed by one of the investigators, masked to treatment group assignment. For the first 40 infants, all infants were examined just before, 12 hours after, and 24 hours after the time of the injection on Monday, Wednesday, and Friday (a total of 9 times per week). Subsequently, when no short-term adverse events were noted after injections, the remaining infants were evaluated 3 times per week. The infants were examined for any unusual physical findings and for the physical signs of toxicity found in older patients: increased fontanel tension, lethargy, vomiting, pallor, extremity tenderness, dry or scaly skin, or unusual pigmentation. All infants with abnormal findings not explainable by the infant's other problems or treatments on the weekly clinical examinations had a blood sample taken before the next scheduled dose. If vitamin A toxicity or any adverse events were noticed or suspected, the attending neonatologist could decide whether to continue treatment. All data collected at the time of 50% patient enrollment were analyzed by the Data Safety and Monitoring Committee to identify any possible adverse events that may be related to vitamin A administration. As appropriate in a management trial, ventilator management and other aspects of clinical care were left to the discretion of the attending physician. Study exit criteria included completion of data collection after 120 days of hospital stay or withdrawal of consent by parents.
Statistical Analyses
A planned sample size of 120 (with a projected 30% attrition due to death or inadequate samples) was estimated to be sufficient to detect a 40% change in serum retinol concentration on study day 28 (the primary outcome), with 80% power at an α level of .05 by analysis of variance. A difference of 40% in retinol levels was used for calculating the sample size because a 40% difference in serum retinol concentration was associated with a change in outcome in the NICHD trial. 4 Statistical analyses for clinical outcomes were performed on the basis of intention to treat. Biochemical outcomes were analyzed for all infants alive and with adequate serum samples at the sampling time. Continuous variables were compared by analysis of variance followed by the Tukey test and categoric variables by the χ 2 test. The SigmaStat version 2.0 software package ( Jandel Corporation, San Rafael, Calif ) was used for statistical analysis.
RESULTS
ELBW infants (n = 120) were enrolled in the trial from November 1999 to August 2001. A total of 269 ELBW infants were screened for eligibility during this period, and 190 (71%) were found eligible. Of the remaining 79 infants (29%), 55 (20%) were not eligible because they were not receiving mechanical ventilation or supplemental oxygen at 24 hours of age, 22 (8%) died, and 2 had major malformations. Informed consent was obtained in 120 of the 190 infants (63%). Consent was declined by parents of 46 infants, and parents of 24 neonates were not available for obtaining consent. The infants who were eligible but not enrolled had demographic characteristics similar to those enrolled in the trial (data not shown). Overall, the mean birth weight of enrolled infants was 709 g and mean gestational age was 25.4 weeks (Table I) . Approximately half (51%) were male, and 65% were black (Table I) .
Of the participating infants, 75% were receiving mechanical ventilation or CPAP, and the remaining 25%, supplemental oxygen without ventilatory assistance at 24 hours of age (Table I ). The mean serum retinol concentrations on study day 1 were comparable among the groups but showed marked variation within each group (Table II) . One infant in the standard regimen and one in the once-per-week regimen died before receiving any doses, and their clinical outcome data were analyzed on the basis of intention to treat.
Biochemical Measures and Safety Evaluations
Mean serum retinol was lower and the proportion of infants with a low serum retinol was higher in the once-per-week regimen as compared with the other two groups (Table II) . Biochemical outcomes in infants surviving to study day 28 who had adequate blood samples for retinol and RDR measurements. Retinol levels, RDR% increase, increase in retinol levels, and RBP shown as mean ± SD, Percentage of infants with retinol <20 µg/dL, retinol >100 µg/dL, RDR >10%, and RBP <2.5 mg/dL expressed as percentage of total infants in that group with measured values. *P < .05 versus other regimens by Tukey test.
Serum retinol concentrations did not differ significantly between the standard and higher dose regimens. The vitamin A concentrations increased significantly from day 1 to day 28 in the standard and high dose regimens (P < .05) and trended higher in the once-per-week group (P = .06). One infant in the higher dose regimen had a serum retinol concentration of 114 µg/dL on study day 28 but was asymptomatic, was not receiving steroids, and a subsequent level at 6 weeks of age was within the normal range (41 µg/dL). One infant in the higher dose regimen had transient mild fullness of the anterior fontanel despite absence of intraventricular hemorrhage or asphyxia, but this fullness had subsided by the next examination in 48 hours. No other biochemical or clinical evidence of toxicity was temporally related or was attributable to vitamin A administration. The percent increase in RDR did not differ significantly among the groups, although there was a trend toward an increase in the incidence of RDR >10% in the once-per-week regimen (Table II) . RBP concentrations were similar among the three groups, and no statistically significant difference was present in the incidence of low RBP, which was >50% in all groups (Table II) . There was moderate correlation between retinol and RBP concentrations on study day 28 (r = 0.64, P < .001). The retinol concentration on study day 28 showed only mild negative correlation with RDR values (r = -0.28, P = .02).
Clinical Outcomes
No significant differences were noted in the incidence of death/BPD, death by 36 weeks' postmenstrual age, or NEC (Table III) . A trend toward a lower incidence of neonatal sepsis and ROP was noted in the higher dose and once-per-week regimens. One hundred of the 120 enrolled ELBW infants (83%) survived to 28 days of age, and 93 (78%) survived to 36 weeks' postmenstrual age. The serum retinol concentrations were unaffected by steroid administration, as only 2 infants (of 100 survivors) were receiving steroids between study day 21 to 28, and the retinol concentrations in these two infants was similar to that of the rest of the group (within ±1 µg/dL of group mean).
Retinol concentrations on study day 1 were not associated with subsequent BPD/death (13 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] µg/dL in survivors without BPD vs 14.5 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] µg/dL in infants with BPD/death [median value; 25%-75% in parentheses; P = .71]). To evaluate if group assignment or retinol levels were associated with BPD/death, a multiple logistic regression analysis was performed with BPD/death as the dependent variable and birth weight, gestational age, sex, race, mechanical ventilation at 24 hours, FIO 2 at 24 hours, mean airway pressure (MAP) at 24 hours, serum retinol on study day 1, and group assignment as independent variables. Only gestational age and MAP at 24 hours were determined to be significantly associated with BPD/death (P < .05).
DISCUSSION
This study evaluated three regimens for the intramuscular administration of vitamin A in ELBW neonates. Compared with the standard NICHD regimen (5000 IU 3 ϫ per week for 4 weeks), administration of a higher dose (10,000 IU 3 ϫ per week for 4 weeks) did not increase vitamin A concentrations or reduce biochemical measures of deficiency, whereas once-per-week dosing (15,000 IU once per week for 4 weeks) led to lower retinol concentrations on study day 28. A limitation of this study is that blood sampling was on study days 1 and 28 only, thereby restricting the pharmacokinetic data that were collected for the study. This strategy limited blood sampling and enabled comparison to the NICHHD trial, 4 in which blood concentrations were obtained at similar periods. Another limitation intrinsic to vitamin A pharmacokinetic studies is that the serum retinol concentrations do not correlate well with liver stores (90% of the total body reserve) until they are very low. 7,10-13 Measurements of RDR and RBP in this study indirectly estimated liver stores and circumvented the limitations of infrequent estimation of serum vitamin A concentrations and the lack of their correlation with liver stores. 4, 7, 11 In addition, there is uncertainty about what serum retinol concentrations are optimal in ELBW neonates, as there are concerns regarding inadequate transport of retinol into tissues, less efficient utilization, and an increased demand for lung repair. 4, 7 This study evaluated higher doses of intramuscular vitamin A than used previously in ELBW neonates. One conclusion of the NICHD trial was that higher doses required evaluation because the serum retinol concentrations were low in a significant proportion of infants despite 5000 IU 3 times per week. 4 Previous regimens ranged from 2000 IU/kg IM per dose on alternate days 7 to 5000 IU IM per dose 3 times per week for 4 weeks. 4, 6 Although higher doses have been used orally, with as much as 5000 IU given per day for 28 days in ELBW neonates, 14 this dose is only equivalent to approximately 2000 IU given by intramuscular injection on alternate days. 15 Vitamin A supplementation in large doses has been generally safe in neonates, with as much as 50,000 IU given as a single dose orally to term neonates. 16, 17 No serious adverse effects could be attributed to the higher dose regimen, although one infant each had transient fullness of the anterior fontanel and a high serum retinol concentration. Marked variability in retinol concentrations were seen in the higher dose group, which may be due to differences in bioavailability or retinol half-life in individual neonates, as has been noted in adults and older children. [18] [19] [20] In view of the lack of improvement in biochemical measures and the possibility of toxicity, the higher dose regimen cannot be recommended, based on our findings. Because smaller infants have a higher incidence of lung disease and corresponding lower reserves 12 and enteral intakes of vitamin A, 2 doses of vitamin A were not adjusted for body weight in this study nor in the NICHD trial. 4 The once-per-week regimen delivered the same weekly dose as the standard regimen but as a more convenient single intramuscular dose. This regimen has the advantages of reducing pain and discomfort caused by the more frequent intramuscular injections of the standard regimen. No toxicity was detected with this regimen. The retinol concentrations were lower and the number of infants with retinol levels in the deficient range was higher as compared with the standard regimen. However, the levels of RBP, RDR, and the incidence of high RDR were not different. It must be noted that the retinol administration in the once-per-week regimen was on study days 1, 8, 15, and 22. Therefore, the retinol concentrations on study day 28 were obtained one week after the last dose, whereas in the standard and higher dose regimens, the administration was 3 times per week (days 1, 3, 5, 8, 10, 24, 26) , and the levels were obtained 2 days after the last dose. In adults and older children, retinol and retinyl palmitate concentrations after intramuscular administration normally peak 48 hours later, persist for about 2 days, and decline within 5 days. [18] [19] [20] Consequently, the retinol concentrations in the higher dose and standard regimens may be higher as compared with those in the once-per-week regimen, as the retinol measurement was done earlier. The explanation is likely, because RDR and RBP were not lower in the once-per-week regimen as compared with the other two regimens, indicating that vitamin A stores may have been similar in magnitude in all three regimens. It is possible that the peak values (which were not measured) with the once-per-week regimen may have been higher than with the other two regimens, as the dose per injection is larger (15,000 IU). Further studies would be needed to determine if it is the peak concentration, trough concentration, or areas under the curve for serum retinol that are most important for clinical outcomes. It is possible that daily or alternate-day dosing with intravenous or oral formulations of vitamin A may be required if trough levels are most important.
This study had adequate statistical power to evaluate pharmacokinetic data but not clinical outcomes. A very large sample size would be required to evaluate equivalence in clinical outcomes between different supplementation regimens. In the NICHD trial that enrolled 807 ELBW neonates, an absolute risk difference of 7% for BPD/death was seen between the supplemented and unsupplemented groups. 4 Our study did not have a placebo arm because multiple studies had already shown vitamin A supplementation to be safe and effective in reducing the incidence of BPD/death. [3] [4] [5] A trend toward a lower incidence of septicemia and ROP was noted in the high dose and once-per-week regimens as compared with the standard regimen, although this study did not have sufficient statistical power to address these observations. In the NICHD trial, although ROP was not evaluated, there was a trend toward lower infection in the vitamin A group. 4 A study with a much larger sample size is required to investigate if a reduction in intramuscular injections or a higher retinol dose improves outcomes of incidence of sepsis or ROP.
It is necessary to consider the generalizability of this study. The mean birth weight and gestational age in this study was 709 g and 25.4 weeks versus 770 g and 26.8 weeks in the NICHD trial, 4 indicating that infants in this study were smaller and more premature. Despite this, the overall rate of death/BPD in the standard regimen group (48%) was lower than in the vitamin A group of the NICHD trial (55%). 4 It is possible that the effects of vitamin A administration may be more evident in populations with a higher incidence of vitamin A deficiency or a higher incidence of BPD (eg, birth weight <750 g or ELBW infants with high ventilator requirements soon after birth).
In conclusion, in view of the lack of improvement in serum retinol, RDR, and RBP, the higher dose regimen may not offer any additional benefits over the standard regimen.
The standard regimen leads to better biochemical measures of vitamin A sufficiency as compared with the once-perweek regimen. Further evaluation of regimens to optimize vitamin A administration and improve important short-term and long-term clinical outcomes in ELBW neonates is required.
